Catalent Inc. (NYSE:CTLT) has a beta of 1.47, a 12-month trailing P/E ratio of 33.91, and a growth ratio of 1.99. The stock’s Relative Strength Index (RSI) is 36.41, with weekly volatility at 2.61% and ATR at 2.91. The CTLT stock’s 52-week price range has touched low of $67.97 and a $127.68 high. Its shares traded lower over the last trading session, losing -1.65% on 05/18/21. The shares fell to a low of $100.30 before closing at $100.34. Intraday shares traded counted 1.22 million, which was -11.04% lower than its 30-day average trading volume of 1.10M. CTLT’s previous close was $102.02 while the outstanding shares total 170.50M.
Investors have identified the Drug Manufacturers – Specialty & Generic company Catalent Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $16.72 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Catalent Inc. (CTLT) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For CTLT, the company has in raw cash 988.1 million on their books with 73.6 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 2.77 billion total, with 1.14 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 3.18 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CTLT sounds very interesting.
Is the stock of CTLT attractive?
In related news, SVP, Technical Operations, Schmidt Kay A sold 1,400 shares of the company’s stock in a transaction that recorded on Mar 22. The sale was performed at an average price of 105.77, for a total value of 148,078. As the sale deal closes, the Chair & CEO, Chiminski John R now sold 183,024 shares of the company’s stock, valued at 19,402,784. Also, Chair & CEO, Chiminski John R sold 42,220 shares of the company’s stock in a deal that was recorded on Mar 18. The shares were price at an average price of 105.16 per share, with a total market value of 4,439,855. Following this completion of acquisition, the SVP & General Counsel, Fasman Steven L now holds 21,647 shares of the company’s stock, valued at 2,262,770. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.30%.
11 out of 14 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Catalent Inc.. 0 analysts has assigned a Sell rating on the CTLT stock. The 12-month mean consensus price target for the company’s shares has been set at $133.90.